Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBP-8088
- Development stage
- Preclinical
- Lead developer
- Coherent Biopharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
CBP-8088 is a bispecific antibody-drug conjugate (ADC) being developed by Coherent Biopharma for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC). Developed using the company's proprietary Bi-XDC technology platform, CBP-8088 is the first PROTAC conjugate drug to feature a bi-specific targeting ligand system. This design allows for the precise delivery of a PROTAC (Proteolysis-Targeting Chimera) payload to tumor cells, where it induces the degradation of specific intracellular proteins to inhibit cancer progression. By combining the specificity of bispecific antibodies with the potent protein-degrading mechanism of PROTACs, CBP-8088 aims to improve both safety and therapeutic efficacy. As of early 2024, the drug is in preclinical development, and its specific molecular targets remain undisclosed.
Beyond the preview
Go deeper on CBP-8088.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBP-8088.